Effect of Ca2+ on GP IIb-IIIa interactions with Integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate

Circulation

Volumn 96, Issue 5, 1997, Pages 1488-1494

  Phillips, David R ^a   Teng, Willie ^a   Arfsten, Ann ^a   Nannizzi Alaimo, Lisa ^a   White, Melanie M ^b   Longhurst, Celia ^b   Shattil, Sanford J ^d   Randolph, Anne ^a   Jakubowski, Joseph A ^c   Jennings, Lisa K ^b   Scarborough, Robert M ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d COR Therapeutics ^*

Author keywords

Calcium; Drugs; Fibrinogen; Glycoproteins; Platelets

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM ION; CITRIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; UNCLASSIFIED DRUG; CALCIUM; EPITOPE; FIBRINOGEN; MONOCLONAL ANTIBODY; PEPTIDE; THROMBIN RECEPTOR;

ARTICLE; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; PLASMA; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; THROMBOSIS PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY; BLOOD; IMMUNOLOGY; METABOLISM; OSMOLARITY; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CALCIUM; CITRIC ACID; EPITOPES; FIBRINOGEN; HUMANS; OSMOLAR CONCENTRATION; PEPTIDES; PLASMA; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX;

EID: 0030610564     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.5.1488     Document Type: Article

References (44)

1. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332: 1553-1559.
2. Topol EJ. Novel antithrombotic approaches to coronary artery disease. Am J Cardiol. 1995;75:27B-33B.
3. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mee CP, Califf RM, Topol EJ. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation. 1995;91: 2151-2157.
4. Genetta TB, Mauro VF. ABCIXIMAB: a new antiaggregant used in angioplasty. Ann Pharmacol. 1996;30:251-257.
5. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996;27:536-542.
6. Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff M, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D, Greenberg CS, Kitt MM, Topol EJ, Califf RM. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 1995;76:1222-1227.
7. Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AA, Charo IF. Design of potent and specific integrin antagonists: peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem. 1993;268: 1066-1073.
8. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost. 1995;74:302-308.
9. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 1988;71:831-843.
10. Coller BS. Platelets and thrombolytic therapy. N Engl J Med. 1990; 322:33-42.
11. Gold K, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, Jordan R, Berger H, Collen D, Coller BS. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest. 1990;86:651-659.
12. ++ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma. Thromb Res. 1990;58:47-60.
13. Rivas GA, Gonzalez-Rodriguez J. Calcium binding to human platelet integrin GPIIb/IIIa and to its constituent glycoproteins: effects of lipids and temperature. Biochem J. 1991;276:35-40.
14. Cierniewski CS, Haas TA, Smith JW, Plow EF. Characterization of cation-binding sequences in the platelet integrin GPIIb-IIIa (αIIbβ3) by terbium luminescence. Biochemistry. 1994;33:12238-12246.
15. Shattil SJ, Brass LF. The interaction of extracellular calcium with the platelet membrane glycoprotein IIb-IIIa complex. Nouv Rev Fr Hematol. 1985;27:211-217.
16. Johnston GI, Heptinstall S. Identity of saturable calcium-binding sites on blood platelets and their involvement in platelet aggregation. Thromb Haemost. 1988;59:54-61.
17. Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem. 1980;255:154-161.
18. Fitzgerald LA, Phillips DR. Calcium regulation of the platelet membrane glycoprotein IIb-IIIa complex. J Biol Chem. 1985;260: 11366-11374.
19. Fujimura K, Phillips DR. Calcium cation regulation of glycoprotein IIb-IIIa complex formation in platelet plasma membranes. J Biol Chem. 1983;258:10247-10252.
20. D'Souza SE, Haas TA, Piotrowicz RS, Byers-Ward V, McGrath DE, Soule HR, Cierniewski C, Plow EF, Smith JW. Ligand and cation binding are dual functions of a discrete segment of the integrin β3 subunit: cation displacement is involved in ligand binding. Cell. 1994;79:659-667.
21. 2+ binding site on the β3-integrins that regulates the dissociation rate for ROD ligands. J Biol Chem. 1996;271:21745-21751.
22. Collen D, Lu HR, Stassen JM, Vreys I, Yasuda T, Bunting S, Gold HK. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost. 1994;71:95-102.
23. Scarborough RM, Rose JW, Naughton MA, Phillips DR, Nannizzi L, Arfsten A, Campbell AA, Charo IF. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J Biol Chem. 1993;268:1058-1065.
24. Charo IF, Nannizzi L, Phillips DR, Hsu MA, Scarborough RM. Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide. J Biol Chem. 1991;266:1415-1421.
25. Kouns WC, Wall CD, White MM, Fox CF, Jennings LK. A conformation-dependent epitope of human platelet glycoprotein. J Biol Chem. 1990;265:20594-20601.
26. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood. 1987;70:307-315.
27. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF, Joshi A, Coller BS, Weisman HF. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIB/IIIa receptors. J Am Coll Cardiol. 1995; 26:1665-1671.
28. Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis J-F, Nasmith J, Fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian lamifiban study. Circulation. 1996;94:899-905.
29. Scarborough RM, Naughton MA, Teng W, Hung DT, Rose J, Vu TH, Wheaton VI, Turck CW, Coughlin SR. Tethered ligand agonist peptides: structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J Biol Chem. 1992;267:13146-13149.
30. Kouns WC, Newman PJ, Puckett KJ, Miller AA, Wall CD, Fox CF, Seyer JM, Jennings LK. Further characterization of the loop structure of platelet glycoprotein IIIa: partial mapping of functionally significant glycoprotein IIIa epitopes. Blood. 1991;78: 3215-3223.
31. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J Biol Chem. 1985;260:11107-11114.
32. Mondoro TH, Wall CD, White MM, Jenning LK. Selective induction of a glycoprotein IIIa ligand-induced binding site by fibrinogen and von Willebrand factor. Blood. 1996;88:3824-3830.
33. Fitzgerald LA, Steiner B, Rail SC Jr, Lo SS, Phillips D. Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone: identity with platelet glycoprotein IIIa and similarity to 'integrin.' J Biol Chem. 1987;262:3936-3939.
34. Gulino D, Boudignon C, Zhang L, Concord E, Rabiet MJ, Marguerie G. Ca2+-binding properties of the platelet glycoprotein IIb ligand-interacting domain. J Biol Chem. 1992;267:1001-1007.
35. Lee JO, Rieu P, Arnaout MA, Liddington R. Crystal structure of the A domain from the a subunit of integrin CR3(CD11b/CD18). Cell. 1995;80:631-638.
36. Loftus JC, O'Toole TE, Plow EF, Glass A, Frelinger AL, Ginsberg MH. A beta3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science. 1990;249: 915-918.
37. Tozer EC, Liddington RC, Sutcliffe MJ, Smeeton AH, Loftus JC. Ligand binding to integrin αIIbβ3 is dependent on a MIDAS-like domain in the β3 subunit. J Biol Chem. 1996;271:21978-21984.
38. Brass L, Shattil S. Identification of the high affinity binding sites for calcium on the surface of human platelets. J Clin Invest. 1984;73: 626-632.
39. Loftus JC, Smith JW, Ginsberg MH. Integrin-mediated cell adhesion: the extracellular face. J Biol Chem. 1994;269:25235-25238.
40. D'Souza SE, Ginsberg MH, Lam SC-T, Plow EF. Chemical cross-linking of arginyl-glycyl-aspartic acid peptides to an adhesion receptor on platelets. J Biol Chem. 1988;263:1-9.
41. Hu DD, Hover JR, Smith JW. Ca2+ suppresses cell adhesion to osteopontin by attenuating binding affinity for integrin αvβ3. J Biol Chem. 1995;270:9917-9925.
42. Gralnick HR, Williams S, McKeown L, Connaghan G, Shafer B, Hansmann K, Vail M, Fenton J. Endogenous platelet fibrinogen surface expression on activated platelets. J Lab Clin Med. 1991;118: 604-613.
43. Legrand C, Dubernard V, Nurden AT. Studies on the mechanism of expression of secreted fibrinogen on the surface of activated human platelets. Blood. 1989;73:1226-1234.
44. Tcheng JE, IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997;349: 1422-1428.